» Authors » Ivan Martinez-Baz

Ivan Martinez-Baz

Explore the profile of Ivan Martinez-Baz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 82
Citations 855
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Vera-Punzano N, Trobajo-Sanmartin C, Navascues A, Echeverria A, Casado I, Ezpeleta C, et al.
Euro Surveill . 2025 Mar; 30(10). PMID: 40084423
No abstract available.
2.
Antunes L, Rojas-Castro M, Lozano M, Martinez-Baz I, Leroux-Roels I, Borg M, et al.
Influenza Other Respir Viruses . 2025 Mar; 19(3):e70081. PMID: 40059069
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included...
3.
Soares P, Machado A, Nicolay N, Monge S, Sacco C, Holm Hansen C, et al.
Euro Surveill . 2025 Feb; 30(8). PMID: 40017392
BackgroundDuring the first year of the COVID-19 pandemic, vaccination programmes targeted children and adolescents to prevent severe outcomes of SARS-CoV-2 infection.AimTo estimate COVID-19 vaccine effectiveness (VE) against hospitalisation due to...
4.
Trobajo-Sanmartin C, Portillo M, Navascues A, Martinez-Baz I, Ezpeleta C, Castilla J
Enferm Infecc Microbiol Clin (Engl Ed) . 2025 Feb; 43(2):93-96. PMID: 39914941
Objective: To assess the pneumonia incidence in Navarre, Spain, in the 2023-2024 season. Methods: Using electronic medical records, we evaluated the incidence of clinical pneumonia, positive pneumococcal antigen cases and...
5.
Martinez-Baz I, Navascues A, Trobajo-Sanmartin C, Pozo F, Fernandez-Huerta M, Olazabal-Arruiz M, et al.
Int J Infect Dis . 2024 Dec; 151:107364. PMID: 39694231
Objective: We estimated the influenza vaccination effectiveness (IVE) in preventing medical consultations and hospitalizations due to influenza during the 2023/24 season. Methods: Two test-negative case-control studies analyzed patients who consulted...
6.
Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al.
Expert Rev Vaccines . 2024 Nov; 23(1):1085-1090. PMID: 39535047
Background: We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years. Research Design And Methods: We linked electronic health...
7.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, ODonnell J, Seve N, et al.
Influenza Other Respir Viruses . 2024 Nov; 18(11):e70009. PMID: 39523781
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at...
8.
Vera-Punzano N, Bullon-Vela V, Miret C, Pardos-Plaza J, Garcia Cenoz M, Godoy P, et al.
Infect Dis Rep . 2024 Oct; 16(5):923-931. PMID: 39452159
This study aims to describe the long-term changes in the knowledge of, and attitudes towards, COVID-19 and its preventive measures in northern Spain. A telephonic survey was performed among household...
9.
Antunes L, Mazagatos C, Martinez-Baz I, Naesens R, Borg M, Petrovic G, et al.
Influenza Other Respir Viruses . 2024 Aug; 18(8):e13360. PMID: 39145535
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in...
10.